EP Wealth Advisors LLC Buys Shares of 15,720 GoodRx Holdings, Inc. $GDRX

EP Wealth Advisors LLC bought a new stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 15,720 shares of the company’s stock, valued at approximately $69,000.

Several other institutional investors have also added to or reduced their stakes in GDRX. Citizens Financial Group Inc. RI purchased a new stake in GoodRx during the 1st quarter valued at $44,000. Jump Financial LLC purchased a new stake in GoodRx during the 1st quarter valued at $49,000. Northwestern Mutual Wealth Management Co. boosted its stake in GoodRx by 20,956.5% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 14,529 shares of the company’s stock valued at $64,000 after purchasing an additional 14,460 shares during the last quarter. Headlands Technologies LLC boosted its stake in GoodRx by 213.2% during the 1st quarter. Headlands Technologies LLC now owns 14,830 shares of the company’s stock valued at $65,000 after purchasing an additional 10,095 shares during the last quarter. Finally, Total Wealth Planning & Management Inc. purchased a new stake in GoodRx during the 4th quarter valued at $68,000. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

GoodRx Price Performance

Shares of GoodRx stock opened at $4.12 on Thursday. GoodRx Holdings, Inc. has a one year low of $3.31 and a one year high of $7.82. The stock’s fifty day moving average is $4.45 and its 200 day moving average is $4.44. The stock has a market cap of $1.43 billion, a P/E ratio of 41.20, a P/E/G ratio of 1.80 and a beta of 1.23. The company has a debt-to-equity ratio of 0.75, a quick ratio of 4.21 and a current ratio of 4.21.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). GoodRx had a return on equity of 8.86% and a net margin of 4.33%.The company had revenue of $203.07 million during the quarter, compared to the consensus estimate of $205.72 million. During the same period in the prior year, the business posted $0.08 earnings per share. GoodRx’s revenue for the quarter was up 1.2% compared to the same quarter last year. Sell-side analysts anticipate that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Raymond James Financial cut GoodRx from a “strong-buy” rating to an “outperform” rating in a report on Friday, August 8th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $6.00 price target on shares of GoodRx in a report on Monday, August 11th. Five equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $5.80.

Insider Buying and Selling

In related news, major shareholder Equity Vii L.P. Spectrum sold 16,016 shares of the firm’s stock in a transaction on Friday, September 5th. The stock was sold at an average price of $4.05, for a total value of $64,864.80. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 4.53% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.